Real-World Evaluation of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• age ≥18 years

• diagnosis of moderate-to-severe HS with Hurley stage II or III

• Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules

• inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors

Locations
Other Locations
China
No. 1 Shuai Fu Yuan, Dongcheng District, Beijing
RECRUITING
Beijing
Time Frame
Start Date: 2025-06-01
Estimated Completion Date: 2026-06-01
Participants
Target number of participants: 50
Related Therapeutic Areas
Hidradenitis Suppurativa
Sponsors
Leads: Peking Union Medical College

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Multicenter Open-Label Interventional Biomarker Study of Lutikizumab in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa or Adult Subjects With Moderate-to-Severe Atopic Dermatitis

A Multicenter Open-Label Interventional Biomarker Study of Lutikizumab in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa or Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Enrollment Status: Recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Phase: Phase 2

A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa

A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa

Enrollment Status: Recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Phase: Phase 3

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Enrollment Status: Recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Phase: Phase 3
View All